Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

Beijing Friendship Hospital, Capital Medical University, Beijing

Beijing Cancer Hospital, Beijing

Beijing Hospital, Beijing

Shengjing Hospital of China Medical University, Shenyang

Affiliated Zhongshan Hospital of Fudan University, Shanghai

Shandong Cancer Hospital, Jinan

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang

Jiangxi Province Cancer Hospital, Nanchang

Hunan Cancer Hospital, Changsha

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Henan Cancer Hospital, Zhengzhou

Zhujiang Hospital of Southern Medical University, Guangzhou

Sun Yat Sen University Cancer Center, Guangzhou

Guangdong Provincial Peoples Hospital, Guangzhou

West China Hospital, Sichuan University, Chengdu

Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital, Chengdu